Natera (NTRA) president sells stock to cover RSU tax obligations
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Natera, Inc.January 20, 2026, he sold 23,205 shares of common stock at $234.7384 per share, leaving 144,992 shares beneficially owned directly after that transaction. On January 21, 2026, he sold an additional 293 shares at $235.00 per share, with 144,699 shares beneficially owned directly afterward.
The footnotes state that both sales were effected to satisfy tax withholding and remittance obligations arising from the vesting of restricted stock units granted on January 27, 2023 and January 28, 2022, under written instructions intended to meet the affirmative defense conditions of Rule 10b5‑1(c) under the Exchange Act.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 23,498 shares ($5,515,960)
Net Sell
2 txns
Insider
Moshkevich Solomon
Role
PRESIDENT, CLINICALDIAGNOSTICS
Sold
23,498 shs ($5.52M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 293 | $235.00 | $69K |
| Sale | Common Stock | 23,205 | $234.7384 | $5.45M |
Holdings After Transaction:
Common Stock — 144,699 shares (Direct)
Footnotes (1)
- The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units (RSUs) and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023. The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 28, 2022.
FAQ
Who is the insider involved in this NTRA Form 4 filing?
The reporting person is Solomon Moshkevich, who serves as President, Clinical Diagnostics at Natera, Inc. (NTRA).
What transaction did Solomon Moshkevich report on January 21, 2026 for Natera (NTRA)?
On January 21, 2026, he reported a sale of 293 shares of Natera common stock at a price of $235.00 per share.